CARsgen Therapeutics Holdings Limited

Representative image of advanced CAR T-cell therapy research and infusion monitoring, reflecting CARsgen Therapeutics’ CT0596 and CT1190B data in multiple myeloma and B-cell lymphoma.

Pharma & Biotech

How CARsgen’s EHA 2026 data could change investor debate around allogeneic CAR T

by Pallavi Madhiraju
June 15, 2026
0 Comments

Find out how CARsgen’s CT0596 and CT1190B data could reshape the allogeneic CAR T race in cancer therapy.

Pharma & Biotech

What CARsgen Therapeutics’ RMB370m manufacturing plan reveals about CAR-T execution risk

by Pallavi Madhiraju
February 13, 2026
0 Comments

CARsgen Therapeutics is expanding CAR-T manufacturing in Shanghai as solid tumor programs near approval. Find out why this matters for scale and adoption.